Transfusion risk analysis with regard to vCJD in France;Évaluation du risque transfusionnel vis-à-vis de la variante de la maladie de Creutzfeldt-Jakob en France

Transfusion Clinique et Biologique

Volumn 13, Issue 5, 2006, Pages 298-303

  Martin, M ^a   Legras, J F ^a   Pouchol, E ^a   Trouvin, J H ^a  

^a DEMEB   (France)

Author keywords

Blood; France; Risk analysis; Transfusion; vCJD

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; FRANCE; HUMAN; INFECTION PREVENTION; INFECTION RISK; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STANDARD;

BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; FRANCE; HUMANS; RISK FACTORS;

EID: 33846679972     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2006.11.003     Document Type: Article

References (37)

1. Afssaps. Analyse du risque de transmission de la nouvelle variante de la maladie de Creutzfeldt-Jakob par le sang et ses dérivés - Recommandations - décembre 2000 (2000)
2. Afssaps. Analyse du risque de transmission de la variante de la maladie de Creutzfeldt-Jakob par les médicaments d'origine humaine et par les produits sanguins labiles - Actualisation des données du rapport du groupe ad hoc de décembre 2000 - février 2002 (2002)
3. Afssaps. Analyse du risque de transmission de la variante de la maladie de Creutzfeldt-Jakob par les médicaments d'origine humaine et par les produits sanguins labiles - Actualisation des données du rapport du groupe ad hoc de décembre 2000 - mars 2003 (2003)
4. Afssaps. Analyse du risque de transmission de la variante de la maladie de Creutzfeldt-Jakob par les produits de santé et par les tissus et fluides d'origine humaine - Actualisation des données du rapport du groupe ad hoc de décembre 2000 - Février 2004 (2004)
5. Afssaps. Évaluation du risque de transmission de l'agent de Creutzfeldt-Jakob par le sang et ses composants - Réunion du groupe d'experts du 16 novembre 2004 - Février 2005 (2005)
6. Hill A.F., Butterworth R.J., Joiner S., et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353 (1999) 183-189
7. Koperek O., Kovacs G.G., Ritchie D., Ironside J.W., Budka H., and Wick G. Disease-associated prion protein in vessel walls. Am. J. Pathol. 161 (2002) 1979-1984
8. Head M.W., Ritchie D., Smith N., et al. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. Am. J. Pathol. 164 (2004) 143-153
9. Bons N., Lehmann S., Mestre-Frances N., Dormont D., and Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion 42 (2002) 513-516
10. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang. 89 (2005) 63-70
11. Hunter N., Foster J., Chong A., et al. Transmission of prion diseases by blood transfusion. J. Gen. Virol. 83 (2002) 2897-2905
12. Saa P., Castilla J., and Soto C. Presymptomatic detection of prions in blood. Science 313 (2006) 92-94
13. Cervenakova L., Yakovleva O., McKenzie C., et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43 (2003) 1687-1694
14. Brown P., Rohwer R.G., Dunstan B.C., MacAuley C., Gajdusek D.C., and Drohan W.N. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38 (1998) 810-816
15. Gregori L., McCombie N., Palmer D., et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 364 (2004) 529-531
16. Lasmezas C.I., Fournier J.G., Nouvel V., et al. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc. Natl. Acad. Sci. USA 98 (2001) 4142-4147
17. Herzog C., Sales N., Etchegaray N., et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 363 (2004) 422-428
18. Houston F., Foster J.D., Chong A., Hunter N., and Bostock C.J. Transmission of BSE by blood transfusion in sheep. Lancet 356 (2000) 999-1000
19. Siso S., Gonzalez L., Houston F., Hunter N., Martin S., and Jeffrey M. The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion. Blood 108 (2006) 745-748
20. Brown P., Gibbs Jr. C.J., Rodgers-Johnson P., et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 35 (1994) 513-529
21. Heye N., Hensen S., and Muller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 343 (1994) 298-299
22. Evatt B., Austin H., Barnhart E., et al. Surveillance for Creutzfeldt-Jakob disease among persons with haemophilia. Transfusion 38 (1998) 817-820
23. Wilson K., Code C., and Ricketts M.N. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 321 (2000) 17-19
24. Wilson K., and Ricketts M.N. A new human genotype prone to variant Creutzfeldt-Jakob disease. BMJ 332 (2006) 1164-1165
25. Llewelyn C.A., Hewitt P.E., Knight R.S., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
26. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., and Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
27. Hewitt P.E., Llewelyn C.A., Mackenzie J., and Will R.G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 91 (2006) 221-230
28. Alperovitch A., and Will R.G. Predicting the size of the vCJD epidemic in France. C. R. Biol. 325 (2002) 33-36
29. Ghani A.C., Ferguson N.M., Donnelly C.A., and Anderson R.M. Predicted vCJD mortality in Great Britain. Nature 406 (2000) 583-584
30. Clarke P., and Ghani A. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J. R. Soc. Interface 2 (2005) 19-31
31. Cooper J.D., and Bird S.M. Predicting incidence of variant Creutzfeldt-Jakob disease from UK dietary exposure to bovine spongiform encephalopathy for the 1940 to 1969 and post-1969 birth cohorts. Int. J. Epidemiol. 32 (2003) 784-791
32. Ghani A.C. Commentary: Predicting the unpredictable: the future incidence of variant Creutzfeldt-Jakob disease. Int. J. Epidemiol. 32 (2003) 792-793
33. Boelle P.Y., Thomas G., Valleron A.J., Cesbron J.Y., and Will R. Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis. Stat. Methods Med. Res. 12 (2003) 221-233
34. Valleron A.J., Boelle P.Y., Will R., and Cesbron J.Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 294 (2001) 1726-1728
35. d'Aignaux J.N., Cousens S.N., and Smith P.G. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science 294 (2001) 1729-1731
36. Chadeau-Hyam M., Tard A., Bird S., et al. Estimation of the exposure of the French population to the BSE agent: comparison of the 1980-1995 consumption of beef products containing mechanically recovered meat in France and the UK, by birth cohort and gender. Stat. Methods Med. Res. 12 (2003) 247-260
37. Chadeau-Hyam M., and Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France. Int. J. Epidemiol. 34 (2005) 46-52